^
    4d
    NRG-GU002: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (clinicaltrials.gov)
    P2/3, N=612, Completed, NRG Oncology | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Oct 2025 | Trial primary completion date: May 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    docetaxel • Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)
    5d
    CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=112, Not yet recruiting, Fudan University
    New P2 trial
    |
    docetaxel • abiraterone acetate • triptorelin • goserelin acetate • Firmagon (degarelix)
    9d
    Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Sep 2026
    Trial completion date
    |
    abiraterone acetate • prednisone • triptorelin • goserelin acetate
    12d
    Synchronous Bilateral Breast Cancer with Heterogeneous Histology: Invasive Ductal and Lobular Carcinoma - A Case Report. (PubMed, Case Rep Oncol)
    She underwent neoadjuvant chemotherapy (doxorubicin/cyclophosphamide followed by paclitaxel), followed by a left radical mastectomy with axillary dissection. Hormonal therapy (goserelin and exemestane) and adjuvant radiotherapy were initiated...Hormone receptor status, tumor biology, and extent of disease all influence treatment decisions. This rare clinical scenario highlights the need for further research and specific management guidelines.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide • exemestane • goserelin acetate
    13d
    Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. (PubMed, ESMO Open)
    This prespecified 5-year follow-up of efficacy outcomes from NATALEE demonstrated that ribociclib + NSAI continued to reduce the risk of recurrence beyond the 3-year treatment window, supporting its use as adjuvant therapy in patients with HR-positive/HER2-negative EBC. An ongoing positive trend for improved OS in favor of ribociclib + NSAI was observed.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
    |
    Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    18d
    A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants (clinicaltrials.gov)
    P1, N=66, Recruiting, EMD Serono Research & Development Institute, Inc. | N=36 --> 66
    Enrollment change
    |
    goserelin acetate
    1m
    Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial (clinicaltrials.gov)
    P2, N=75, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    goserelin acetate • leuprolide acetate for depot suspension
    1m
    A real-world observational study on the trends of PSA and testosterone changes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) after treatment with goserelin microspheres combined with novel hormonal agents (NHA). (ChiCTR2500109081)
    P2, N=60, Not yet recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P2 trial • Real-world evidence
    |
    goserelin acetate
    2ms
    RTOG 0815: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov)
    P3, N=1538, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed
    Trial completion
    |
    bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
    2ms
    Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov)
    P3, N=239, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2029 --> Sep 2025
    Trial completion • Trial completion date
    |
    bicalutamide • triptorelin • goserelin acetate • flutamide • leuprolide acetate for depot suspension • orteronel (TAK 700) • Suprefact (buserelin acetate)
    2ms
    ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov)
    P4, N=10, Completed, University of Colorado, Denver | Recruiting --> Completed | N=228 --> 10 | Trial completion date: Mar 2028 --> Jul 2025 | Trial primary completion date: Mar 2028 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • bicalutamide • goserelin acetate • flutamide • leuprolide acetate for depot suspension
    2ms
    EVANGELINE: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=87, Recruiting, Atossa Therapeutics, Inc. | N=214 --> 87 | Trial completion date: Sep 2026 --> Apr 2027 | Trial primary completion date: Feb 2026 --> Nov 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    goserelin acetate